The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
08/07/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
Register for Updates
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
NCT06415721
Recruiting
Alcohol Use Disorders are currently positioned as the third leading cause of preventable death in the United States, constituting a humanitarian crisis with substantial financial burden on society and medical facilities. While several pharmacological interventions exist, 60% of individuals who seek these treatments relapse to alcohol within 6 months. These high relapse rates are due in part to elevated brain response to alcohol cues in the environment. This study seeks to evaluate the efficacy o... Read More
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
08/07/2025
Locations: VA Palo Alto Health Care System, Palo Alto, California
Conditions: Alcohol Use Disorder, Alcohol Abuse, Alcoholism, Drinking Behavior, Drinking Problem
Register for Updates
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06348108
Recruiting
This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) tar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of Calfornia, San Francisco, San Francisco, California
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891
Recruiting
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Lexicon Investigational Site (4037), Scottsdale, Arizona +74 locations
Conditions: Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Register for Updates
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941
Recruiting
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/07/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona +53 locations
Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Register for Updates
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
NCT06098430
Recruiting
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments. Primary Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pe... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
08/07/2025
Locations: University of Colorado Hospital, Aurora, Colorado +3 locations
Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Register for Updates
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449
Recruiting
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site, Irvine, California +213 locations
Conditions: Polymyositis, Dermatomyositis
Register for Updates
National Liver Cancer Screening Trial
NCT06084234
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/07/2025
Locations: University of Southern California, Los Angeles, California +16 locations
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Register for Updates
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
NCT05897788
Recruiting
There is growing recognition of the need for approaches to initiate treatment wherever patients touch the health care system, including the Emergency Department (ED). Most research has focused on initiation of medications for opioid use disorder (MOUDs) in the ED rather than ensuring continued treatment post-discharge. The investigators propose to adapt evidence-based interventions to support patients' complex needs and facilitate continued treatment, rather than discharging them and having them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Opioid Use Disorder, Opioid Dependence With Current Use (Disorder)
Register for Updates
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06052306
Recruiting
Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: City of Hope - Duarte Cancer Center, Duarte, California +29 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
NCT06502379
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/07/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607
Recruiting
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site 006, Mobile, Alabama +34 locations
Conditions: Asthma
Register for Updates